Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

5 evidence topics · 3 sources

Monotherapy trials: concomitant MAO-B inhibitor permitted

“not receiving medications to treat Parkinson’s disease (e.g., levodopa) other than concomitant stable dose of an MAO-B inhibitor.” (opens the prescribing information at this quote)

“TEMPO-1 and -2 enrolled patients with early Parkinson's disease (with or without an MAO-B inhibitor) and TEMPO-3 enrolled patients who are on fixed-dose levodopa and had motor fluctuations.” (opens the source at this quote in a new tab)

Adjunctive trial: fixed background levodopa

“minimum stable dose of levodopa of 400 mg per day divided at least 3 or 4 times daily depending on dose formulation; and a good response to levodopa in the judgement of the investigator.” (opens the prescribing information at this quote)

“In this trial, 507 patients were randomized 1:1 to receive JUVMO 5 mg to 15 mg (N = 252) or placebo (N = 255) once daily as adjunctive therapy to the pre-study levodopa dose. No changes in levodopa were allowed during study participation.” (opens the prescribing information at this quote)

Adjusting other dopaminergic medications for dyskinesia

“Consider decreasing the dosage of JUVMO or other dopaminergic medications if dyskinesia occurs.” (opens the prescribing information at this quote)

Antipsychotic medications in patients with Parkinson's disease

“In addition, certain medications used to treat psychosis may exacerbate the symptoms of PD.” (opens the prescribing information at this quote)

Anticipated role alongside existing therapies for advanced disease

“Tavapadon's efficacy and safety-tolerability profile could enable its utility in early Parkinson's disease, becoming a near-term complementary asset to AbbVie's existing symptomatic therapies for advanced Parkinson's disease.” (opens the source at this quote in a new tab)